Hornstein I, Schwarz C, Ebbing S, Hoppe-Lotichius M, Otto G, Lang H, Musholt T J
Department of General, Visceral and Transplantation Surgery, University Medicine of the Johannes, Gutenberg University Mainz, Mainz, Germany.
Langenbecks Arch Surg. 2015 Apr;400(3):333-9. doi: 10.1007/s00423-015-1293-z. Epub 2015 Mar 1.
Only limited data exist on the treatment and outcome of adrenal metastases that derive from different primary tumor entities. Due to the lack of evidence, it is difficult to determine the indication for surgical resection.
We assessed the outcome of 45 patients (28 men, 17 women) with adrenal metastases who underwent surgery (1990-2014). The median age at the time of adrenal surgery was 62 years (range 44-77 years). We were able to evaluate follow-up data of 41 patients.
Primary tumor types were liver n = 12 (hepatocellular carcinoma n = 9, cholangiocellular carcinoma n = 2, sarcoma n = 1), upper GI tract n = 5 (esophagus n = 2, stomach n = 3), lung n = 9, kidney n = 6, neuroendocrine tumors n = 3, colon n = 2, ovarial n = 2, melanoma n = 2, others n = 4. The overall median survival time was 14 months (95 % CI 8.375-19.625). The survival rates at 1, 2, 5, and 10 years were 60, 31, 21, and 11 %, respectively. There were statistically significant differences in the survival time according to the resection status (R0 vs. R1/R2) (p < 0.001) and the type of the primary tumor (p = 0.009), while the metachronous or synchronous occurrence of adrenal metastases did not affect the prognosis.
Resection of adrenal metastases can improve the survival if patients are carefully selected, the tumor is completely resected, and the intervention is integrated into a multidisciplinary oncologic treatment strategy.
关于源自不同原发肿瘤实体的肾上腺转移瘤的治疗及转归,仅有有限的数据。由于缺乏证据,难以确定手术切除的指征。
我们评估了45例(28例男性,17例女性)接受手术治疗(1990 - 2014年)的肾上腺转移瘤患者的转归。肾上腺手术时的中位年龄为62岁(范围44 - 77岁)。我们能够评估41例患者的随访数据。
原发肿瘤类型为肝脏n = 12例(肝细胞癌n = 9例,胆管细胞癌n = 2例,肉瘤n = 1例),上消化道n = 5例(食管n = 2例,胃n = 3例),肺n = 9例,肾n = 6例,神经内分泌肿瘤n = 3例,结肠n = 2例,卵巢n = 2例,黑色素瘤n = 2例,其他n = 4例。总体中位生存时间为14个月(95%可信区间8.375 - 19.625)。1年、2年、5年和10年生存率分别为60%、31%、21%和11%。根据切除状态(R0与R1/R2)(p < 0.001)和原发肿瘤类型(p = 0.009),生存时间存在统计学显著差异,而肾上腺转移瘤的异时性或同时性发生并不影响预后。
如果仔细选择患者、肿瘤完全切除且干预措施纳入多学科肿瘤治疗策略,切除肾上腺转移瘤可提高生存率。